CELL — Phenomex Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
- $98.79m
- $67.83m
- $78.60m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.37 | ||
| Price to Tang. Book | 0.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.75 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.27% | ||
| Return on Equity | -57.01% | ||
| Operating Margin | -129.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 31.3 | 56.69 | 64.3 | 85.39 | 78.59 | 80.26 | 108.14 | 25.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PhenomeX Inc., formerly Berkeley Lights, Inc., is a functional cell biology company. The Company enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The Company enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company’s platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.
Directors
- Gregory Lucier CHM (57)
- Eric Hobbs CEO (44)
- Igor Khandros CFD (66)
- Kurt Wood CFO
- Keith Breinlinger CTO (46)
- Stuart Merkadeau GCN (59)
- John Chiminski DRC
- James Rothman DRC (69)
- Sarah Boyce IND (49)
- Jessica Hopfield IND (56)
- Siddhartha Kadia IND (51)
- Michael Moritz IND (66)
- Elizabeth Nelson IND (61)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- April 5th, 2011
- Public Since
- July 17th, 2020
- No. of Shareholders
- 22
- No. of Employees
- 285
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 98,795,621
- Address
- 5858 Horton Street, Suite 320, EMERYVILLE, 94608-2183
- Web
- https://www.phenomenex.com/
- Phone
- +1 5108582855
- Auditors
- KPMG LLP
Upcoming Events for CELL
Q3 2023 Berkeley Lights Inc Earnings Release
Similar to CELL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Phenomex share price?
As of Today at 01:17 UTC, shares in Phenomex are trading at $0.58. This share price information is delayed by 15 minutes.
How has the Phenomex share price performed this year?
Shares in Phenomex last closed at $0.58 and the price had moved by -86.6% over the past 365 days. In terms of relative price strength the Phenomex share price has underperformed the S&P500 Index by -88.49% over the past year.
What are the analyst and broker recommendations for Phenomex?
The overall consensus recommendation for Phenomex is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Phenomex dividend yield?
Phenomex does not currently pay a dividend.
Does Phenomex pay a dividend?
Phenomex does not currently pay a dividend.
When does Phenomex next pay dividends?
Phenomex does not currently pay a dividend.
How do I buy Phenomex shares?
To buy shares in Phenomex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Phenomex?
As of the previous close price of $0.58, shares in Phenomex had a market capitalisation of $57.20m.
Where are Phenomex shares listed?
Here are the trading details for Phenomex:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CELL
What kind of share is Phenomex?
Based on an overall assessment of its quality, value and momentum Phenomex is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Phenomex share price forecast for 2023?
The analyst consensus target price for shares in Phenomex is $5.71. That is 879.27% above the last closing price of $0.58.
Analysts covering Phenomex currently have a consensus Earnings Per Share (EPS) forecast of -$1.03 for the next financial year.
What is the trend in the Phenomex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Phenomex. Over the past six months, its share price has underperformed the S&P500 Index by -74.78%.
As of the last closing price of $0.58, shares in Phenomex were trading -64.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Phenomex PE Ratio?
The Phenomex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Phenomex?
Phenomex's management team is headed by:
- Gregory Lucier - CHM
- Eric Hobbs - CEO
- Igor Khandros - CFD
- Kurt Wood - CFO
- Keith Breinlinger - CTO
- Stuart Merkadeau - GCN
- John Chiminski - DRC
- James Rothman - DRC
- Sarah Boyce - IND
- Jessica Hopfield - IND
- Siddhartha Kadia - IND
- Michael Moritz - IND
- Elizabeth Nelson - IND